Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury

Traumatic Brain Injury Clinical Trial

Official title: Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury

Status Not yet recruiting

Clinical Trial Summary

Traumatic brain injury (TBI) causes acute deficits in cerebral perfusion which may lead to secondary injury and worse outcomes. Inhaled nitric oxide (iNO) is a vasodilator that increases cerebral blood flow and is clinically used for hypoxic respiratory failure in neonates and adults. The investigators will perform a randomized controlled trial of iNO treatment in TBI patients acutely after injury. The investigators will then assess perfusion changes with optic neuromonitoring, blood biomarkers, and 6 month clinical outcomes.

Clinical Trial Description

The objective of this study is to show that inhaled nitric oxide can increase blood flow in the brain after traumatic brain injury, attenuating brain injury and resulting in improved long-term function.

The investigators will use optical brain monitoring to determine changes in cerebral perfusion and metabolism by iNO treatment in TBI subjects. Within 24 hours of enrollment, TBI subjects meeting the inclusion criteria without exclusion criteria will undergo 8 hour sessions of monitoring (4 hours on iNO, 4 hours on standard respiratory therapy) for 3 days. During this time, Noninvasive Neuro-optic Monitoring (NNOM) device will be placed on the scalp and cerebral perfusion and metabolism parameters will be monitored to assess for therapeutic effect of iNO. There will be within-subject comparison of cerebral perfusion and metabolism on and off iNO. Also, there will be within-group comparison of cerebral perfusion and metabolism on days when iNO is given first vs days when iNO is given at a second session. Additionally, these parameters from this group will compared to a parallel group of TBI patients receiving 8 hours of only standard respiratory therapy for 3 days.

The investigators will assess the safety profile of iNO use in TBI subjects. During the course of iNO therapy in the initial 3 days, study subjects will be monitored for methemoglobinemia, hypotension, neurological exam changes, and any other adverse events. These outcomes will be monitored for 2 weeks following the iNO treatment. Additionally, the investigators will assess blood-based biomarkers of injury with blood draws at the end of each iNO treatment session in TBI subjects for 3 days. During the initial three days of the trial, blood draws will be performed at the end of each session to detect biomarkers. Specifically, biomarkers that have been shown to correlate with injury severity such as GFAP, NFL, UCHL-1, tau, and S100B will be monitored at the end of iNO session and standard respiratory therapy session. This will be performed by using a novel assay termed SIMOA, a sensitive detection method for blood-based biomarkers.

As an exploratory aim, the investigators will compare 6-month GOS-E outcomes of the patients who received iNO to those who received standard respiratory therapy. Patients will be assessed for their functional status at the time of 6 month follow up. Each patient in this study will be compared to a patient who had similar demographic background, mechanism of injury (fall, motor vehicle crash, assault), and severity of injury (based on Glasgow Coma Scale) from an existing database. ;

Related Conditions & MeSH terms

• Brain Injuries
• Brain Injuries, Traumatic
• Traumatic Brain Injury
• Wounds and Injuries

• NCT number: NCT05616910
• Study type: Interventional
• Source: University of Pennsylvania
• Contact: Samuel Shin
• Phone: 267-734-3042
• Email: samuel.shin@pennmedicine.upenn.edu
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: September 1, 2024
• Completion date: August 31, 2027